Skip to main content
Top
Published in: Journal of Translational Medicine 1/2018

Open Access 01-12-2018 | Research

Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model

Authors: Fei-Fei Shen, Yan Wang, Yi-Fei Wang, Rui-Dan Zheng, Jian-Chun Xian, Jun-Ping Shi, Ying Qu, Yu-Wei Dong, Ming-Yi Xu, Lun-Gen Lu

Published in: Journal of Translational Medicine | Issue 1/2018

Login to get access

Abstract

Background

A model was constructed using clinical and serum variables to discriminate between chronic hepatitis B (CHB) patients with and without significant necroinflammatory activity (score 4–18 vs. score 0–3).

Methods

Consecutive CHB patients who underwent liver biopsy were divided into two sequential groups: a training group (n = 401) and a validation group (n = 401). Multivariate analysis identified alanine aminotransferase, γ-glutamyltransferase, prothrombin time and albumin as independent predictors of necroinflammatory activity.

Results

The area under the receiver operating characteristic curve was 0.826 for the training group and 0.847 for the validation group. Using a cut-off score of H ≤ 0.375, significant necroinflammatory activity (score 4–18) was excluded with high accuracy [78.2% negative predictive value (NPV), 72% positive predictive value (PPV), and 90.8% sensitivity] in 238 (59.4%) of 401 patients in the training group and with the same certainty (88.1% NPV, 61.2% PPV, and 95.1% sensitivity) among 204 (50.9%) of 401 patients in the validation group. Similarly, applying a cut-off score of H > 0.720, significant necroinflammatory activity was correctly identified with high accuracy (90.8% PPV, 57.7% NPV, and 92.0% specificity) in 150 (37.4%) of 401 patients in the training group and with the same certainty (91.8% PPV, 64.6% NPV, and 95.4% specificity) in 188 (46.9%) of 401 patients in the validation group.

Conclusions

A predictive model based on easily accessible variables identified CHB patients with and without significant necroinflammatory activity with a high degree of accuracy. This model may decrease the need for liver biopsy for necroinflammatory activity grading in 72.1% of CHB patients.
Literature
1.
go back to reference Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed
2.
go back to reference Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed
3.
go back to reference Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16:e82–8.CrossRefPubMed Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16:e82–8.CrossRefPubMed
4.
go back to reference Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet. 2016;388:1081–8.CrossRefPubMedPubMedCentral Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet. 2016;388:1081–8.CrossRefPubMedPubMedCentral
5.
go back to reference Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed
7.
go back to reference Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442–50.CrossRefPubMed Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442–50.CrossRefPubMed
8.
go back to reference Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99:1160–74.CrossRefPubMed Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99:1160–74.CrossRefPubMed
9.
go back to reference Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefPubMed Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefPubMed
10.
go back to reference Forns X, Ampurdanes S, Llover JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–92.CrossRefPubMed Forns X, Ampurdanes S, Llover JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–92.CrossRefPubMed
11.
go back to reference Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–75.CrossRefPubMed Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–75.CrossRefPubMed
12.
go back to reference Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005;42:1437–45.CrossRefPubMed Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005;42:1437–45.CrossRefPubMed
13.
go back to reference Ho AS, Cheng CC, Lee SC, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein A1. J Biomed Sci. 2010;17:58.CrossRefPubMedPubMedCentral Ho AS, Cheng CC, Lee SC, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein A1. J Biomed Sci. 2010;17:58.CrossRefPubMedPubMedCentral
14.
go back to reference Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in HBeAg-positive patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25:1569–77.CrossRefPubMed Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in HBeAg-positive patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25:1569–77.CrossRefPubMed
15.
go back to reference Poynard T, Deckmyn O, Munteanu M, et al. Awareness of the severity of liver disease reexamined using software combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open. 2015;5:e010017.CrossRefPubMedPubMedCentral Poynard T, Deckmyn O, Munteanu M, et al. Awareness of the severity of liver disease reexamined using software combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open. 2015;5:e010017.CrossRefPubMedPubMedCentral
16.
go back to reference Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.CrossRefPubMed Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.CrossRefPubMed
17.
go back to reference Rüeger S, Bochud PY, Dufour JF, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2015;64:1605–15.CrossRefPubMed Rüeger S, Bochud PY, Dufour JF, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2015;64:1605–15.CrossRefPubMed
18.
go back to reference European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRef European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRef
19.
go back to reference Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.CrossRefPubMed Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.CrossRefPubMed
20.
go back to reference Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol. 2014;12:16–26.CrossRefPubMed Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol. 2014;12:16–26.CrossRefPubMed
21.
go back to reference Feng L, Sun K, Zhang J, et al. A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study. BMJ Open. 2015;5(9):e008032.CrossRefPubMedPubMedCentral Feng L, Sun K, Zhang J, et al. A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study. BMJ Open. 2015;5(9):e008032.CrossRefPubMedPubMedCentral
22.
go back to reference Kobayashi Y, Kawaguchi Y, Mizuta T, Fujimoto K, et al. Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol. 2011;46:529–35.CrossRefPubMed Kobayashi Y, Kawaguchi Y, Mizuta T, Fujimoto K, et al. Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol. 2011;46:529–35.CrossRefPubMed
23.
go back to reference Gish RG, Given BD, Lai CL, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antivir Res. 2015;121:47–58.CrossRefPubMed Gish RG, Given BD, Lai CL, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antivir Res. 2015;121:47–58.CrossRefPubMed
24.
go back to reference Michelle L, Benjamin JH, Imad N, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. Hepatology. 2007;47:760–7.CrossRef Michelle L, Benjamin JH, Imad N, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. Hepatology. 2007;47:760–7.CrossRef
25.
go back to reference Loomba R, Rao F, Zhang L, et al. Genetic covariance between γ-glutamyl transpeptidase and fatty liver risk factors: role of β2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139:836–45.CrossRefPubMedPubMedCentral Loomba R, Rao F, Zhang L, et al. Genetic covariance between γ-glutamyl transpeptidase and fatty liver risk factors: role of β2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139:836–45.CrossRefPubMedPubMedCentral
26.
go back to reference Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222–30.CrossRefPubMed Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222–30.CrossRefPubMed
27.
go back to reference Chen SS, Yu KK, Ling QX, et al. Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis. Sci Rep. 2016;6:33093.CrossRefPubMedPubMedCentral Chen SS, Yu KK, Ling QX, et al. Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis. Sci Rep. 2016;6:33093.CrossRefPubMedPubMedCentral
Metadata
Title
Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model
Authors
Fei-Fei Shen
Yan Wang
Yi-Fei Wang
Rui-Dan Zheng
Jian-Chun Xian
Jun-Ping Shi
Ying Qu
Yu-Wei Dong
Ming-Yi Xu
Lun-Gen Lu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2018
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-018-1538-z

Other articles of this Issue 1/2018

Journal of Translational Medicine 1/2018 Go to the issue